OrthoPediatrics Competitors

OrthoPediatrics (NASDAQ:KIDS) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for OrthoPediatrics and iRhythm Technologies, as provided by MarketBeat.com.

OrthoPediatrics currently has a consensus target price of $55.80, suggesting a potential upside of 12.61%. iRhythm Technologies has a consensus target price of $212.6667, suggesting a potential upside of 60.19%. Given iRhythm Technologies' higher possible upside, analysts clearly believe iRhythm Technologies is more favorable than OrthoPediatrics.

Valuation and Earnings

This table compares OrthoPediatrics and iRhythm Technologies' top-line revenue, earnings per share (EPS) and valuation.

OrthoPediatrics has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

OrthoPediatrics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.

Profitability

This table compares OrthoPediatrics and iRhythm Technologies' net margins, return on equity and return on assets.

Insider & Institutional Ownership

71.7% of OrthoPediatrics shares are owned by institutional investors. 33.6% of OrthoPediatrics shares are owned by insiders. Comparatively, 3.1% of iRhythm Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

OrthoPediatrics beats iRhythm Technologies on 8 of the 14 factors compared between the two stocks.

OrthoPediatrics (NASDAQ:KIDS) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Valuation and Earnings

This table compares OrthoPediatrics and Glaukos' top-line revenue, earnings per share (EPS) and valuation.

Glaukos has higher revenue and earnings than OrthoPediatrics. Glaukos is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

71.7% of OrthoPediatrics shares are owned by institutional investors. 33.6% of OrthoPediatrics shares are owned by insiders. Comparatively, 8.7% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for OrthoPediatrics and Glaukos, as provided by MarketBeat.com.

OrthoPediatrics currently has a consensus target price of $55.80, suggesting a potential upside of 12.61%. Glaukos has a consensus target price of $66.3750, suggesting a potential downside of 20.16%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, equities analysts clearly believe OrthoPediatrics is more favorable than Glaukos.

Profitability

This table compares OrthoPediatrics and Glaukos' net margins, return on equity and return on assets.

Risk and Volatility

OrthoPediatrics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500.

Summary

Glaukos beats OrthoPediatrics on 8 of the 14 factors compared between the two stocks.

Cantel Medical (NYSE:CMD) and OrthoPediatrics (NASDAQ:KIDS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Cantel Medical and OrthoPediatrics' top-line revenue, earnings per share and valuation.

Cantel Medical has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

95.0% of Cantel Medical shares are owned by institutional investors. Comparatively, 71.7% of OrthoPediatrics shares are owned by institutional investors. 10.7% of Cantel Medical shares are owned by company insiders. Comparatively, 33.6% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Cantel Medical and OrthoPediatrics, as reported by MarketBeat.

Cantel Medical presently has a consensus price target of $71.50, suggesting a potential downside of 14.64%. OrthoPediatrics has a consensus price target of $55.80, suggesting a potential upside of 12.61%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, analysts clearly believe OrthoPediatrics is more favorable than Cantel Medical.

Profitability

This table compares Cantel Medical and OrthoPediatrics' net margins, return on equity and return on assets.

Volatility & Risk

Cantel Medical has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Summary

Cantel Medical beats OrthoPediatrics on 9 of the 14 factors compared between the two stocks.

NuVasive (NASDAQ:NUVA) and OrthoPediatrics (NASDAQ:KIDS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares NuVasive and OrthoPediatrics' top-line revenue, earnings per share and valuation.

NuVasive has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than NuVasive, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

71.7% of OrthoPediatrics shares are owned by institutional investors. 0.9% of NuVasive shares are owned by company insiders. Comparatively, 33.6% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for NuVasive and OrthoPediatrics, as reported by MarketBeat.

NuVasive presently has a consensus price target of $64.8667, suggesting a potential downside of 5.59%. OrthoPediatrics has a consensus price target of $55.80, suggesting a potential upside of 12.61%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, analysts clearly believe OrthoPediatrics is more favorable than NuVasive.

Profitability

This table compares NuVasive and OrthoPediatrics' net margins, return on equity and return on assets.

Volatility & Risk

NuVasive has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Summary

NuVasive beats OrthoPediatrics on 8 of the 14 factors compared between the two stocks.

Merit Medical Systems (NASDAQ:MMSI) and OrthoPediatrics (NASDAQ:KIDS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Merit Medical Systems and OrthoPediatrics' top-line revenue, earnings per share and valuation.

Merit Medical Systems has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

99.5% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 71.7% of OrthoPediatrics shares are owned by institutional investors. 4.7% of Merit Medical Systems shares are owned by company insiders. Comparatively, 33.6% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Merit Medical Systems and OrthoPediatrics, as reported by MarketBeat.

Merit Medical Systems presently has a consensus price target of $64.3750, suggesting a potential upside of 4.67%. OrthoPediatrics has a consensus price target of $55.80, suggesting a potential upside of 12.61%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, analysts clearly believe OrthoPediatrics is more favorable than Merit Medical Systems.

Profitability

This table compares Merit Medical Systems and OrthoPediatrics' net margins, return on equity and return on assets.

Volatility & Risk

Merit Medical Systems has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Summary

Merit Medical Systems beats OrthoPediatrics on 9 of the 14 factors compared between the two stocks.

AtriCure (NASDAQ:ATRC) and OrthoPediatrics (NASDAQ:KIDS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares AtriCure and OrthoPediatrics' top-line revenue, earnings per share and valuation.

OrthoPediatrics has lower revenue, but higher earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

94.7% of AtriCure shares are owned by institutional investors. Comparatively, 71.7% of OrthoPediatrics shares are owned by institutional investors. 5.8% of AtriCure shares are owned by company insiders. Comparatively, 33.6% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for AtriCure and OrthoPediatrics, as reported by MarketBeat.

AtriCure presently has a consensus price target of $66.00, suggesting a potential upside of 0.15%. OrthoPediatrics has a consensus price target of $55.80, suggesting a potential upside of 12.61%. Given OrthoPediatrics' higher possible upside, analysts clearly believe OrthoPediatrics is more favorable than AtriCure.

Volatility & Risk

AtriCure has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Profitability

This table compares AtriCure and OrthoPediatrics' net margins, return on equity and return on assets.

Summary

OrthoPediatrics beats AtriCure on 7 of the 13 factors compared between the two stocks.